Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 7/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17713984 | 0.97 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MAPK1LMNADPP4 | |
| Formaldehyde SCHEMBL27853879 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPK1LMNADPP4 | |
| SCHEMBL16984947 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNADPP4 | |
| SCHEMBL15649175 | 0.84 | EGFR (0.39) | SMN1; SMN2ALDH1A1MAPK1LMNADPP4 | |
| SCHEMBL15524835 | 0.81 | PDE4A (0.34) | SMN1; SMN2ALDH1A1MAPK1LMNAKMO | |
| SCHEMBL15170169 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1MAPK1LMNADPP4 | |
| SCHEMBL18113766 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1LMNAKMO | |
| SCHEMBL15170666 | 0.80 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1MAPK1LMNAKMO | |
| SCHEMBL374759 | 0.79 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1LMNAKMO | |
| Hydrochloric Acid SCHEMBL10558900 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1MAPK1LMNAKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514782-B | Synthesis method of baratinib related substances | 江苏海悦康医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-116514782-A | Synthesis method of baratinib related substances | 江苏海悦康医药科技有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-110981816-B | Synthesis method of 4-amino-2, 6-dimethoxypyrimidine | 天和药业股份有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-110981816-A | Synthesis method of 4-amino-2, 6-dimethoxypyrimidine | 扬州天和药业有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110028502-B | Preparation method of kinase inhibitor drug intermediate | 济南周行医药科技有限公司 | 2020-02-14 | — | — | CN | claimed |
| CN-110028502-A | A kind of preparation method of kinase inhibitors drug intermediate | 济南周行医药科技有限公司 | 2019-07-19 | — | — | CN | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-116514782-B | Synthesis method of baratinib related substances | 江苏海悦康医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116514782-B | Synthesis method of baratinib related substances | 江苏海悦康医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4281454-B1 | PROCESS FOR MAKING IBRUTINIB | SYNTHON BV (NL) | 2025-03-05 | — | — | EP | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2014054053-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-04-10 | — | — | WO | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| CN-102448955-A | Aminopyrimidine Anticancer Compounds | OSI PHARM INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | SMN1; SMN2 564/4885ALDH1A1 1828/4885MAPK1 1372/4885 |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | SMN1; SMN2 1215/4885ALDH1A1 1117/4885MAPK1 290/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | SMN1; SMN2 65/4885ALDH1A1 2359/4885MAPK1 243/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | SMN1; SMN2 1215/4885ALDH1A1 1117/4885MAPK1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.